Dossier · Private startup · 4 independent sources
Sequentify
Last updated: Jul 31, 2026
Israeli genomics company developing InfiniSeq, a targeted next-generation sequencing library-preparation workflow and analysis pipeline designed to make high-throughput sequencing simpler, faster, and more affordable. Its products are sold for research use only, with stated applications spanning oncology, hematology, carrier screening, infectious-disease surveillance, animal science, and broader genomic research.
Visit WebsiteCompany Overview
Sequentify develops products used before a sequencing instrument is loaded, addressing the library-preparation bottleneck rather than manufacturing sequencing hardware. Its InfiniSeq workflow combines reagents, target-specific probes, and indexes in a kit intended to create sequencing-ready libraries through a four-step process. The company says the workflow takes approximately 3.15 hours, permits samples to be pooled after the first step, and is compatible with manual work, entry-level automation, and high-end liquid handlers. Its analysis offering is positioned as a plug-and-play secondary-analysis pipeline tailored to InfiniSeq, while the company says customers retain ownership and control of their data and intermediate files.
The technical proposition is a targeted, flexible alternative to more complex probe-capture workflows and more constrained amplicon methods. Sequentify says its probes include the motifs needed for library construction, reducing ligation and internal purification steps, and that panels can range from small focused designs to roughly 1 Mb of target footprint. Each probe includes a unique molecular identifier, which the company says supports consensus generation, PCR-noise correction, and low variant-allele-frequency calling; the site states a claimed detection limit as low as 0.5% in suitable use cases. Those are company-reported performance claims and should be confirmed against independent validation data, sample types, sequencing platforms, and reproducibility studies.
The commercial portfolio includes oncology and hematology panels, an ACMG secondary-findings panel, a 216-gene carrier-screening panel, a primate-parentage panel, a COVID-19 panel, custom panels, and the InfiniSeq Analysis pipeline. The company explicitly labels its products research use only and says they are not accredited for diagnostic purposes, so current traction should be read as research, translational, and laboratory-workflow adoption rather than evidence of cleared clinical diagnostics. Public evidence includes customer testimonials from a Haifa University laboratory, the Weizmann Institute, and ODIN Bioscience on the company website; a 2023 release reported Stanford use of Sequentify kits for hematological-malignancy sequencing. The company also lists Gamidor and HekaBio as distributors, indicating an effort to reach laboratories beyond direct sales.
Competition comes from incumbent sequencing-platform vendors and established library-preparation ecosystems, including Illumina, Thermo Fisher Scientific, and Roche, as well as targeted-panel and workflow specialists such as ArcherDX/IDT, Twist Bioscience, and QIAGEN. Sequentify’s potential edge is workflow simplicity, early pooling, custom-panel flexibility, UMI support, platform agnosticism, and a stated ISO 13485 accreditation for manufacturing NGS kits. These advantages matter only if they translate into comparable analytical performance, lower total cost per reportable sample, dependable supply, and easy integration into validated laboratory procedures.
The dual-use case is credible but indirect. The same targeted sequencing and sample-processing capabilities used in clinical research can support pathogen surveillance, antimicrobial-resistance monitoring, outbreak investigation, and population screening. Sequentify’s infectious-disease and COVID-19 materials make that adjacency concrete, and an Israel Innovation Authority record describes its rapid, cost-conscious sequencing technology for oncology, infectious disease, and carrier screening. However, the public record does not establish defense contracts, military deployment, or operational biosecurity use. Strategic value therefore rests on resilient diagnostic and public-health infrastructure potential, not on proven defense revenue. Key diligence questions are independent validation of low-frequency detection, actual customer and distributor throughput, RUO-to-clinical regulatory strategy, recurring consumables economics, and evidence that the company can scale manufacturing and support internationally.
Dual-Use Assessment
Sequentify's targeted sequencing and library-preparation workflow has substantive civilian and security-adjacent applicability: infectious-disease surveillance, outbreak investigation, antimicrobial-resistance monitoring, and population screening can use the same capabilities as commercial genomic research. The public evidence supports a public-health resilience thesis, but does not establish defense contracts, military deployment, or operational biosecurity use; the dual-use score is therefore meaningful but moderate rather than exceptional.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Sequentify is a credible strategic-priority signal for a dual-use deep-tech database because it targets a real NGS workflow bottleneck with a consumables-and-analysis model and has public evidence of research-laboratory use, distributors, an Israel Innovation Authority record, and an announced $7 million financing. The case is not an investment recommendation: the company remains private and early-stage, its products are RUO rather than accredited diagnostics, and public information does not verify current revenue, retention, financing status, or independent performance. The most important diligence is whether InfiniSeq delivers repeatable cost and throughput advantages after full validation and workflow switching costs.
Strategic Value to U.S.-Israel Alliance
Sequentify could contribute to resilient genomic infrastructure by lowering the operational burden of targeted sequencing and enabling smaller laboratories to process more samples. That is strategically relevant to public-health surveillance and outbreak response, where distributed capacity, rapid turnaround, and control of genomic data can matter. The company lists infectious-disease products and public-health-oriented applications, but the available evidence supports an enabling platform rather than a dedicated defense product. Its strategic value should consequently be assessed through deployment readiness, supply-chain resilience, data governance, validation quality, and ability to serve allied laboratories—not through an assumed military market.
Key Technologies
- InfiniSeq targeted NGS library preparation
- Probe-based target selection with built-in library motifs
- Early sample indexing and pooled-sample workflows
- Unique molecular identifiers for PCR-noise correction and consensus calling
- Custom targeted-panel design up to approximately 1 Mb target footprint
- Platform-agnostic sequencing workflow integration
- InfiniSeq secondary-analysis pipeline with clinical annotations
Use Cases & Applications
- Targeted oncology and circulating-tumor-DNA research panels
- Hematology and minimal-residual-disease research workflows
- Carrier screening and ACMG secondary-findings research
- Infectious-disease and COVID-19 genomic surveillance
- Outbreak investigation and antimicrobial-resistance monitoring
- Custom genomic research panels at academic or reference laboratories
- Primate parentage and animal-science genotyping
- Distributed high-throughput sample processing for public-health laboratories
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work; the research methodology documents how evidence is graded, what counts as an independent source, and why some profiles are excluded from search indexing.
This record lists 8 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Sequentify official website Canonical company website describing InfiniSeq, products, analysis, applications, RUO status, and customer testimonials.
- Sequentify technology page Company-reported four-step 3.15-hour workflow, pooled samples, target footprints, UMI use, low-VAF claim, and ISO 13485/RUO statements.
- Sequentify products page Lists oncology, hematology, carrier-screening, COVID-19, custom, primate-parentage, and analysis products; states products are research use only.
- Sequentify company page Lists management, Rehovot address, distributors, mission, and ISO 13485 accreditation claim.
- Israel Innovation Authority company record Government record identifies Sequentify as founded in 2021 with 13 employees and describes its genomic sequencing technology and target markets.
- Stanford to use Sequentify kits for Hematological Malignancies NGS Sequencing 2023 release reporting Stanford use of Sequentify kits for hematological-malignancy sequencing.
- Sequentify awarded grant for infectious disease sequencing panel Company-issued release distributed by PR Newswire concerning Israel Innovation Authority support for an infectious-disease sequencing panel.
- Democratizing Genomics: Sequentify Raises $7M Reputable media coverage of the announced $7 million financing and company positioning.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Related sector
See the General Technology sector page for market context, related subcategories, and other Israeli companies in this part of the database.